Chronic Obstructive Pulmonary Disease (COPD)Phase 1NCT04756960
Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects
A Phase 1 study testing CHF6001 in people with Chronic Obstructive Pulmonary Disease (COPD) and COPD, run by Chiesi Farmaceutici S.p.A. at 1 site in United Kingdom.
Trial summary
The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male subjects. Read more about this study
- Who is it for?
- Ages 30 to 55 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease (COPD), COPD
- What is being tested?
- CHF6001
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 10 Mar 2021to 29 Apr 2021
- Phase
- Phase 1
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 55 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Subject's written informed consent obtained prior to any study-related procedure;
- Able to understand the study procedures, the risks involved and ability to be trained to use correctly the inhalers and to generate sufficient Peak Inspiratory Flow (PIF), using the In-Check device and Placebo inhaler;
- Male subjects aged 30 to 55 years inclusive;
- Body mass index (BMI) within the range of 18 to 35 kg/m^2 inclusive;
- Non- or ex-smoker who smoked < 5 pack years and who stopped smoking > 1 year prior to screening;
- Good physical and mental status;
Show all 11Show fewer
- Vital signs at screening within limits;
- 12-lead digitised Electrocardiogram (12-lead ECG) in triplicate considered as normal;
- Lung function measurements within normal limits at screening;
- Regular bowel movements at screening;
- Males with non-pregnant Women of Childbearing Potential (WOCBP) partners: they and/or their partner of childbearing potential must be willing to use a highly effective birth control method in addition to the male condom from the signature of the informed consent and until 90 days after the follow-up visit. Males with pregnant WOCBP partner: they must be willing to use male contraception (condom) from the signature of the informed consent and until 90 days after the follow-up visit.
Who cannot join
- Participation in another clinical trial with an investigational drug in the 3 months or 5 half-lives of that investigational drug (whichever is longer) preceding the administration of the study drug;
- Clinically relevant and uncontrolled respiratory, cardiac, hepatic (including Gilbert syndrome), gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorder;
- Clinically relevant abnormal laboratory values;
- Subjects with history of breathing problems;
- Positive to Human Immunodeficiency Virus 1/Human Immunodeficiency Virus 2 (HIV1/HIV2) serology at screening;
- Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening;
Show all 20Show fewer
- Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior screening or prior to treatment;
- Positive urine test for cotinine;
- Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test;
- Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen;
- Intake of non-permitted concomitant medications in the predefined period;
- Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or before treatment;
- Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the trial;
- Unsuitable veins for repeated venipuncture;
- Heavy caffeine drinker;
- Abnormal haemoglobin level at screening;
- Subjects using e-cigarettes within 6 months prior to screening;
- Subjects been involved in a study involving a 14^C-labeled drug within the 12 months prior to enrollment;
- Subjects with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to Day-1;
- Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks or which has not resolved within 14 days prior to screening and before treatment.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 Following a Single Inhaled Dose Co-administered With an Intravenous Radiolabelled Microtracer Dose in Healthy Volunteers
The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male subjects.
Read the detailed description
This clinical trial is a single centre Phase I study, with a single dose, non-randomized, open-label, uncontrolled design. A total of 8 healthy male subjects were included in the study.
The aim was to assess the absolute bioavailability, the mass balance, and routes of elimination of CHF6001 (Tanimilast) in healthy male subjects, using [14^C]-radiolabelled drug substance, administered as an intravenous (iv) infusion concomitantly with an inhaled (inh) non-radiolabelled dose of CHF6001.
Standard safety assessments were conducted during the study, including safety blood and urine laboratory tests, vital signs, physical examinations, ECGs, and assessment of any adverse events (AE). Blood, urine, and feces samples were collected for pharmacokinetic (PK) analyses.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), COPD
- Being tested
- CHF6001
- Keywords
- Chronic Obstructive Pulmonary Disease, COPD, Healthy subjects, Phase I, CHF6001, Tanimilast, Chiesi Farmaceutici S.p.A
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CHF6001Drug
4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of [14^C]-labelled CHF6001
| Study group | Role | What they receive |
|---|---|---|
| CHF6001 | Experimental | single dose of CHF6001 dry-powder inhaler (DPI) co-administered with an intravenous microdose of [14^C]-labelled CHF6001 Receives: Drug: CHF6001 |
What is being measured
The primary outcome is the main question the study is designed to answer.
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total
AUC(0-t_iv) for [14^C] total in plasma.
AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration.
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total
C(max_iv) for [14^C] total in plasma.
C(max_iv)=Peak plasma concentration after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total
t(max_iv) for [14^C] total.
t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total
Area under curve extrapolated to infinity (AUC(0-∞_iv) for [14^C] total in plasma.
AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total
Terminal half-life t(1/2_iv) for [14^C] total and CHF6001.
t1/2_iv=Terminal half-life, after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total
Blood to plasma ratio for [14^C] total.
Measured: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001
AUC(0-t_iv) for [14^C] CHF6001 in plasma.
AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001
C(max_iv) for [14^C] CHF6001 in plasma.
C(max_iv)=Peak plasma concentration, after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001
t(max_iv) for [14^C] CHF6001.
t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001
Area under curve extrapolated to infinity (AUC0-∞_iv) for [14^C] CHF6001 in plasma.
AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001
Terminal half-life t(1/2_iv) for [14^C] CHF6001 in plasma.
t(1/2_iv)=Terminal half-life, after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001
Volume of distribution during the terminal phase (Vz_iv) of [14^C] CHF6001 in plasma.
Vz_iv=Volume of distribution during the terminal phase, after intravenous (iv) infusion administration
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001
Vdss_iv=Volume of distribution is calculated at steady-state for [14^C] CHF6001 in plasma, after intravenous (iv) infusion administration.
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001
Systemic plasma clearance for [14^C] CHF6001.
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001
Blood to plasma ratio for [14^C] CHF6001.
Measured: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.
PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001
AUC(0-t)_inh for CHF6001 in plasma.
AUC(0-t)_inh=Area Under the curve, from 0 to the last quantifiable concentration after inhalation of CHF6001
Measured: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
PK Parameter -- C(max_inh) -- Plasma -- CHF6001
C(max_inh) for CHF6001 in plasma.
C(max_inh)=Peak plasma concentration after inhalation of CHF6001
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
PK Parameter -- t(max_inh) -- Plasma -- CHF6001
t(max_inh) for CHF6001 in plasma.
t(max_inh)=Time to reach the Cmax after inhalation of CHF6001
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001
AUC(0-∞_inh) for CHF6001 in plasma.
AUC(0-∞_inh)=Area under curve extrapolated to infinity after inhalation of CHF6001
Measured: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
PK Parameter -- t(1/2_inh) -- Plasma -- CHF6001
t(1/2_inh) for CHF6001 in plasma.
t(1/2_inh)=Terminal half-life, after inhalation of CHF6001
Measured: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001
Absolute inhaled bioavailability for CHF6001.
F_inh=Inhaled absolute bioavailability based on AUC(0-∞) after inhalation of CHF6001 F_inh=(AUC(0-∞)_inh x Dose_iv)/ (AUC(0-∞)_iv x Dose_inh).
Measured: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C] Total
Urine excreted fraction for cumulative [14^C] total.
Measured: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C]-CHF6001
Urine excreted fraction for cumulative [14^C]-CHF6001.
Measurements in urine were performed. All measured values were below the limit of quantification of the bioanalytical method.
Measured: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C] Total
Fecal excreted fraction for cumulative [14^C] total.
Measured: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C]-CHF6001
Fecal excreted fraction for cumulative [14^C]-CHF6001.
Measured: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C] Total
Urine and fecal excreted fraction for cumulative [14^C] total.
Measured: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C]-CHF6001
Urine and Fecal excreted fraction for cumulative [14^C]-CHF6001.
Measured: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Feb 2021
- Study start10 Mar 2021
- Primary completion29 Apr 2021
- Study completion29 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Chronic Obstructive Pulmonary Disease (COPD)Studies of the same condition, open and under way.
- More trials run by Chiesi Farmaceutici S.p.A.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04756960
- Sponsor's protocol ID
- CLI-06001AA1-02
- Other IDs
- 2020-004201-31
- Status last verified
- Sep 2023
- First submitted
- 8 Feb 2021
- Last updated
- 18 Mar 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 Following a Single Inhaled Dose Co-administered With an Intravenous Radiolabelled Microtracer Dose in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT04756960
- Acronym / sponsor ID
- CLI-06001AA1-02
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), COPD
- Keywords
- Chronic Obstructive Pulmonary Disease, COPD, Healthy subjects, Phase I, CHF6001, Tanimilast, Chiesi Farmaceutici S.p.A
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry (pharma, biotech, devices)
- Study start
- 10 Mar 2021 (actual)
- Primary completion
- 29 Apr 2021 (actual)
- Study completion
- 29 Apr 2021 (actual)
- First posted
- 16 Feb 2021 (actual)
- Results
- Posted 18 Mar 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male subjects.
Detailed description
This clinical trial is a single centre Phase I study, with a single dose, non-randomized, open-label, uncontrolled design. A total of 8 healthy male subjects were included in the study.
The aim was to assess the absolute bioavailability, the mass balance, and routes of elimination of CHF6001 (Tanimilast) in healthy male subjects, using [14^C]-radiolabelled drug substance, administered as an intravenous (iv) infusion concomitantly with an inhaled (inh) non-radiolabelled dose of CHF6001.
Standard safety assessments were conducted during the study, including safety blood and urine laboratory tests, vital signs, physical examinations, ECGs, and assessment of any adverse events (AE). Blood, urine, and feces samples were collected for pharmacokinetic (PK) analyses.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CHF6001 | Experimental | Drug: CHF6001single dose of CHF6001 dry-powder inhaler (DPI) co-administered with an intravenous microdose of [14^C]-labelled CHF6001 |
Who may qualify
- Ages
- 30 to 55 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Subject's written informed consent obtained prior to any study-related procedure;
- Able to understand the study procedures, the risks involved and ability to be trained to use correctly the inhalers and to generate sufficient Peak Inspiratory Flow (PIF), using the In-Check device and Placebo inhaler;
- Male subjects aged 30 to 55 years inclusive;
- Body mass index (BMI) within the range of 18 to 35 kg/m^2 inclusive;
- Non- or ex-smoker who smoked < 5 pack years and who stopped smoking > 1 year prior to screening;
Key exclusion criteria (20 listed)
- Participation in another clinical trial with an investigational drug in the 3 months or 5 half-lives of that investigational drug (whichever is longer) preceding the administration of the study drug;
- Clinically relevant and uncontrolled respiratory, cardiac, hepatic (including Gilbert syndrome), gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorder;
- Clinically relevant abnormal laboratory values;
- Subjects with history of breathing problems;
- Positive to Human Immunodeficiency Virus 1/Human Immunodeficiency Virus 2 (HIV1/HIV2) serology at screening;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CHF60014 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of [14^C]-labelled CHF6001 | Drug | CHF6001 |
Primary outcome
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
AUC(0-t_iv) for [14^C] total in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration.
PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
C(max_iv) for [14^C] total in plasma. C(max_iv)=Peak plasma concentration after intravenous (iv) infusion administration
PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
t(max_iv) for [14^C] total. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Area under curve extrapolated to infinity (AUC(0-∞_iv) for [14^C] total in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Terminal half-life t(1/2_iv) for [14^C] total and CHF6001. t1/2_iv=Terminal half-life, after intravenous (iv) infusion administration
PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total
Time frame: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.
Blood to plasma ratio for [14^C] total.
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
AUC(0-t_iv) for [14^C] CHF6001 in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration
PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
C(max_iv) for [14^C] CHF6001 in plasma. C(max_iv)=Peak plasma concentration, after intravenous (iv) infusion administration
PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
t(max_iv) for [14^C] CHF6001. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration
PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Area under curve extrapolated to infinity (AUC0-∞_iv) for [14^C] CHF6001 in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration
PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Terminal half-life t(1/2_iv) for [14^C] CHF6001 in plasma. t(1/2_iv)=Terminal half-life, after intravenous (iv) infusion administration
PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Volume of distribution during the terminal phase (Vz_iv) of [14^C] CHF6001 in plasma. Vz_iv=Volume of distribution during the terminal phase, after intravenous (iv) infusion administration
PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Vdss_iv=Volume of distribution is calculated at steady-state for [14^C] CHF6001 in plasma, after intravenous (iv) infusion administration.
PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.
Systemic plasma clearance for [14^C] CHF6001.
PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.
Blood to plasma ratio for [14^C] CHF6001.
PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001
Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
AUC(0-t)_inh for CHF6001 in plasma. AUC(0-t)_inh=Area Under the curve, from 0 to the last quantifiable concentration after inhalation of CHF6001
PK Parameter -- C(max_inh) -- Plasma -- CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
C(max_inh) for CHF6001 in plasma. C(max_inh)=Peak plasma concentration after inhalation of CHF6001
PK Parameter -- t(max_inh) -- Plasma -- CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
t(max_inh) for CHF6001 in plasma. t(max_inh)=Time to reach the Cmax after inhalation of CHF6001
PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001
Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
AUC(0-∞_inh) for CHF6001 in plasma. AUC(0-∞_inh)=Area under curve extrapolated to infinity after inhalation of CHF6001
PK Parameter -- t(1/2_inh) -- Plasma -- CHF6001
Time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.
t(1/2_inh) for CHF6001 in plasma. t(1/2_inh)=Terminal half-life, after inhalation of CHF6001
PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001
Time frame: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours
Absolute inhaled bioavailability for CHF6001. F_inh=Inhaled absolute bioavailability based on AUC(0-∞) after inhalation of CHF6001 F_inh=(AUC(0-∞)_inh x Dose_iv)/ (AUC(0-∞)_iv x Dose_inh).
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C] Total
Time frame: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.
Urine excreted fraction for cumulative [14^C] total.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C]-CHF6001
Time frame: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.
Urine excreted fraction for cumulative [14^C]-CHF6001. Measurements in urine were performed. All measured values were below the limit of quantification of the bioanalytical method.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C] Total
Time frame: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.
Fecal excreted fraction for cumulative [14^C] total.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C]-CHF6001
Time frame: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.
Fecal excreted fraction for cumulative [14^C]-CHF6001.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C] Total
Time frame: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).
Urine and fecal excreted fraction for cumulative [14^C] total.
PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C]-CHF6001
Time frame: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).
Urine and Fecal excreted fraction for cumulative [14^C]-CHF6001.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Chronic Obstructive Pulmonary Disease (COPD)
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing CHF6001 in people with Chronic Obstructive Pulmonary Disease (COPD) and COPD, run by Chiesi Farmaceutici S.p.A. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 18 Mar 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total (time frame: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.). The study lists 27 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2024.